Immatics (IMTX) Non-cash Items (2020 - 2021)

Immatics' (IMTX) quarterly Non-cash Items came in at $27.4 million in Q2 2021, down 85.71% quarter-over-quarter from $191.8 million in Q3 2020.

Immatics (IMTX) Non-cash Items (2020 - 2021) Analysis & Trends

Immatics has disclosed Non-cash Items across 2 years of filings, most recently posting $27.4 million for Q2 2021.

Non-cash Items for Q2 2021 came in at $27.4 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2021 was $27.4 million (changed N/A YoY), and the FY2020 annual result was $180.0 million, changed N/A from the prior year.
Non-cash Items came in at $27.4 million for Q2 2021 at Immatics, down from $191.8 million in the prior quarter.
In the past five years, Non-cash Items ranged from a high of $191.8 million in Q3 2020 to a low of $27.4 million in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Immatics	14.67 Bn	14.67 Bn	-

Download Data